- Published on
Emergency And Acute Medicine – Procedural Sedation
Procedural sedation involves the administration of sedative agents with or without analgesics to facilitate diagnostic or therapeutic procedures while minimizing pain and anxiety and maintaining cardiorespiratory function. Informed consent should be obtained prior to sedation. Preparation includes ensuring availability of airway equipment such as bag-valve masks, oral and nasal airways, laryngoscopes, endotracheal tubes, suction, and a defibrillator. An emergency cart with resuscitation medications, including naloxone and flumazenil, must be accessible. Continuous monitoring with cardiac monitor, pulse oximetry, and blood pressure measurement is required. Oxygen should be administered to maintain saturation above 95%. All medications should be clearly labeled and prepared at the bedside. Patients must be observed throughout the procedure and recovery period until they are awake, alert, and have returned to baseline function.
Pre-sedation assessment includes a focused history of past medical problems, prior anesthesia complications, medications, allergies, and time of last oral intake. Physical examination should include vital signs, cardiopulmonary and neurologic assessment, and airway evaluation. Risk factors for difficult ventilation include beards, abnormal facial anatomy, obesity, edentulous state, and underlying pulmonary or cardiac disease. Difficult airway predictors include short neck, large tongue, small mandible, high Mallampati score, and signs of airway obstruction such as stridor, drooling, or dysphagia.
Sedative and analgesic medications may cause dose-dependent respiratory depression, and combining agents increases the risk of hypoxia and apnea. For painless procedures, single agents such as methohexital, chloral hydrate (in children), etomidate, pentobarbital, midazolam, or ketamine may be used. Painful procedures typically require agents with analgesic properties such as ketamine, fentanyl with midazolam, propofol with fentanyl, etomidate with fentanyl, nitrous oxide, dexmedetomidine, or ketamine–propofol combinations.
Methohexital is a short-acting barbiturate producing unconsciousness and amnesia without analgesia. It has rapid onset and short duration but may cause respiratory depression and hypotension. Pentobarbital is used primarily for painless diagnostic procedures and may cause central nervous system and respiratory depression. Midazolam, a benzodiazepine, provides anxiolysis and amnesia but no analgesia; it has rapid onset and short duration when given intravenously. Its effects are potentiated by opioids and may be reversed with flumazenil. Chloral hydrate is used in young children for painless procedures but has prolonged effects and risk of respiratory depression. Dexmedetomidine provides sedation, anxiolysis, and some analgesia, with predictable reductions in heart rate and blood pressure.
Etomidate provides rapid sedation and amnesia with minimal cardiovascular effects but lacks analgesia and may cause myoclonus, nausea, and transient adrenal suppression. Ketamine produces dissociative anesthesia with analgesia and preservation of airway reflexes. It may increase heart rate, blood pressure, intracranial pressure, and secretions, and can cause emergence reactions, particularly in adults. Nitrous oxide offers rapid-onset analgesia and anxiolysis for short procedures but is contraindicated in pregnancy, pneumothorax, and bowel obstruction. Fentanyl and remifentanil are short-acting opioids providing analgesia with risk of respiratory depression, hypotension, and rarely chest wall rigidity. Propofol provides rapid-onset sedation and amnesia but no analgesia; it may cause significant respiratory depression and hypotension.
Reversal agents include naloxone for opioid-induced respiratory depression and flumazenil for benzodiazepine reversal. Naloxone may precipitate acute withdrawal in opioid-dependent patients. Flumazenil may provoke seizures or withdrawal in patients dependent on benzodiazepines. Both agents have shorter durations of action than many sedatives, requiring continued monitoring for recurrent sedation.
Patients may be discharged once they are awake, alert, hemodynamically stable, ambulatory, able to tolerate oral intake, and have a responsible adult for supervision and transport. Admission is indicated for post-procedural complications, inability to ambulate, persistent sedation, or lack of appropriate supervision.
Key principles include continuous cardiorespiratory monitoring during and after sedation, readiness with airway adjuncts and resuscitation equipment, cautious dosing—especially when combining medications—and careful observation through recovery to minimize complications.
Procedural sedation involves the administration of sedative agents with or without analgesics to facilitate diagnostic or therapeutic procedures while minimizing pain and anxiety and maintaining cardiorespiratory function. Informed consent should be obtained prior to sedation. Preparation includes ensuring availability of airway equipment such as bag-valve masks, oral and nasal airways, laryngoscopes, endotracheal tubes, suction, and a defibrillator. An emergency cart with resuscitation medications, including naloxone and flumazenil, must be accessible. Continuous monitoring with cardiac monitor, pulse oximetry, and blood pressure measurement is required. Oxygen should be administered to maintain saturation above 95%. All medications should be clearly labeled and prepared at the bedside. Patients must be observed throughout the procedure and recovery period until they are awake, alert, and have returned to baseline function.
Pre-sedation assessment includes a focused history of past medical problems, prior anesthesia complications, medications, allergies, and time of last oral intake. Physical examination should include vital signs, cardiopulmonary and neurologic assessment, and airway evaluation. Risk factors for difficult ventilation include beards, abnormal facial anatomy, obesity, edentulous state, and underlying pulmonary or cardiac disease. Difficult airway predictors include short neck, large tongue, small mandible, high Mallampati score, and signs of airway obstruction such as stridor, drooling, or dysphagia.
Sedative and analgesic medications may cause dose-dependent respiratory depression, and combining agents increases the risk of hypoxia and apnea. For painless procedures, single agents such as methohexital, chloral hydrate (in children), etomidate, pentobarbital, midazolam, or ketamine may be used. Painful procedures typically require agents with analgesic properties such as ketamine, fentanyl with midazolam, propofol with fentanyl, etomidate with fentanyl, nitrous oxide, dexmedetomidine, or ketamine–propofol combinations.
Methohexital is a short-acting barbiturate producing unconsciousness and amnesia without analgesia. It has rapid onset and short duration but may cause respiratory depression and hypotension. Pentobarbital is used primarily for painless diagnostic procedures and may cause central nervous system and respiratory depression. Midazolam, a benzodiazepine, provides anxiolysis and amnesia but no analgesia; it has rapid onset and short duration when given intravenously. Its effects are potentiated by opioids and may be reversed with flumazenil. Chloral hydrate is used in young children for painless procedures but has prolonged effects and risk of respiratory depression. Dexmedetomidine provides sedation, anxiolysis, and some analgesia, with predictable reductions in heart rate and blood pressure.
Etomidate provides rapid sedation and amnesia with minimal cardiovascular effects but lacks analgesia and may cause myoclonus, nausea, and transient adrenal suppression. Ketamine produces dissociative anesthesia with analgesia and preservation of airway reflexes. It may increase heart rate, blood pressure, intracranial pressure, and secretions, and can cause emergence reactions, particularly in adults. Nitrous oxide offers rapid-onset analgesia and anxiolysis for short procedures but is contraindicated in pregnancy, pneumothorax, and bowel obstruction. Fentanyl and remifentanil are short-acting opioids providing analgesia with risk of respiratory depression, hypotension, and rarely chest wall rigidity. Propofol provides rapid-onset sedation and amnesia but no analgesia; it may cause significant respiratory depression and hypotension.
Reversal agents include naloxone for opioid-induced respiratory depression and flumazenil for benzodiazepine reversal. Naloxone may precipitate acute withdrawal in opioid-dependent patients. Flumazenil may provoke seizures or withdrawal in patients dependent on benzodiazepines. Both agents have shorter durations of action than many sedatives, requiring continued monitoring for recurrent sedation.
Patients may be discharged once they are awake, alert, hemodynamically stable, ambulatory, able to tolerate oral intake, and have a responsible adult for supervision and transport. Admission is indicated for post-procedural complications, inability to ambulate, persistent sedation, or lack of appropriate supervision.
Key principles include continuous cardiorespiratory monitoring during and after sedation, readiness with airway adjuncts and resuscitation equipment, cautious dosing—especially when combining medications—and careful observation through recovery to minimize complications.
0 Comments
